Discovery Knows No Bounds

Discovery knows no bounds

© Copyright 2019 Regenerative Medicine Minnesota

Phase I study of delivery of autologous bone marrow derived mononuclear cells to myopathic right ventricle in patients with Ebstein anomaly during surgical intervention

Research Grant Recipient: Kimberly Holst, MD

Grant Period: 2016-2018

Award Value: $500,000

Site: Mayo Clinic

In no-cost extension to enroll additional patients in study

Read Holst’s Year 1 Progress Report here

Read Holst’s most recent NCE Interim Progress Report here

The goal of this Phase I study is to establish the safety and feasibility of intramyocardial injection of autologous bone marrow derived mononuclear cells (BM-MNC) into the myopathic right ventricle of patients with Ebstein anomaly (EA) at time of elective cardiac surgery.

Dr. Holst is a general and thoracic surgery resident at Mayo Clinic and a resident in the Clinician Investigator Training Program.